We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > active ulcerative colitis

News List

Janssen Submits Application to European Medicines Agency Seeking Approval of STELARA (ustekinumab) for Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis firstwordpharma
January 09, 2019
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a Group Type II Variation Application to the European Medicines Agency (EMA) seeking approval of STELARA®(ustekinumab) for the treatment of adults with moderately
Janssen Submits Application to European Medicines Agency Seeking Approval of STELARA (ustekinumab) for Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis firstwordpharma
January 09, 2019
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a Group Type II Variation Application to the European Medicines Agency (EMA) seeking approval of STELARA®(ustekinumab) for the treatment of adults with moderately
FDA accepts sNDA for Xeljanz for the treatment of adult patients with active ulcerative colitis cphi-online
July 17, 2017
Anticipated Prescription Drug User Fee Act (PDUFA) action date for the sNDA is March 2018 .